• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Better medication adherence leads to better outcomes in hepatitis C

News
Article

Patients with hepatitis C virus (HCV) who were more adherence to their pegylated interferon and ribavirin treatment were more likely to achieve both an early and sustained virologic response.

Patients with hepatitis C virus (HCV) who were more adherent to their pegylated interferon and ribavirin treatment were more likely to achieve both an early (EVR, decrease of ≥2 log10 HCV RNA at 12 weeks) and sustained virologic response (SVR, undetectable HCV RNA 24 weeks after end of treatment), according to a study published in the September 20, 2011 edition of the Annals of Internal Medicine.

Using the "Veteran Affairs Hepatitis C Clinical Case Registry," researchers retrospectively identified a cohort of 5,706 adult HCV (genotypes 1, 2, 3, and 4) patients receiving ≥1 prescription for pegylated interferon and ribavirin between January 2003 and December 2006, and whom had pre- and post-treatment viral loads measured. Adherence was assessed at 12-week intervals using pharmacy refill records.

In total, researchers found 1,787 of 3,014 (59%) patients with HCV genotype 1 or 4 and 867 of 978 (89%) patients with genotype 2 or 3 achieved EVR, and 901 of 1,929 (47%) patients with genotype 1 or 4 and 620 of 905 (69%) patients with genotype 2 or 3 achieved SVR. In both genotype subgroups, there was a statistically significant association between increasing adherence to interferon and ribavirin and achievement of EVR (P<.001 for all). Moreover, in patients with HCV genotype 1 or 4, increasing drug adherence was associated with a statistically significant increased achievement of SVR; however, a similar association for genotype 2 or 3 was not seen. Of note, adherence declined for both drugs over time, but adherence to interferon therapy always remained higher than ribavirin. Co-administration of growth factors or thyroid medication; however, positively influenced adherence to antiviral therapy.

SOURCE

Lo Re V III, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes. Ann Intern Med 2011;155:353–360.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.